Search

Displaying results 2291 - 2300 of 4590 in total
  1. Drug

    Lenacapavir

    go.drugbank.com/drugs/DB15673
    ApprovedInvestigational

    [L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.

  2. Drug

    Chlorpheniramine

    go.drugbank.com/drugs/DB01114
    ApprovedInvestigational

    A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less dr...

    Mixtures: Up and Up Cold Relief, Up and Up Childrens Multi Symptom Cold Pain Relief Plus
  3. Drug

    Periciazine

    go.drugbank.com/drugs/DB01608
    Approved

    Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.

  4. Drug

    Cupric Chloride

    go.drugbank.com/drugs/DB09131
    Approved

    Cupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

  5. Drug

    Tenocyclidine

    go.drugbank.com/drugs/DB01520
    IllicitInvestigational

    Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.

  6. Drug

    ECT-001 expanded cord blood

    go.drugbank.com/drugs/DB21745
    Investigational

    ECT-001 expanded cord blood is umbilical cord blood (UCB) that has been co-cultured and expanded with the small molecule agonist [UM-171].

    Synonyms: UM-171 expanded cord blood
  7. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.

  8. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site. … The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels.

  9. Drug

    Ritiometan

    go.drugbank.com/drugs/DB13267
    Approved

    Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.

  10. Drug

    Levamisole

    go.drugbank.com/drugs/DB00848
    ApprovedInvestigationalVet approvedWithdrawn

    [A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer.